Clinical trials: Corneal Defect
Keratoconus
Performance and Safety Assessment of T4020 in Managing Corneal Epithelial Defect Following Epi-off Accelerated Crosslinking
The purpose of this study is to assess the performance and safety of T4020 versus saline solution.
- Trial name
- NCT02979054
- Testing
- T4020
- Where
- 4 sites in Bulgaria, France and 2 more
- Volunteers
- 157 people
- Sponsor
- Laboratoires Thea
Persistent Corneal Epithelial Defect
A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial Defects
The objective of this study is to evaluate the safety and effectiveness of topical KIO-201 in patients with persistent corneal epithelial defects (PED). KIO-201 will be administered six (6) times per day while awake for 4 weeks.
- Trial name
- NCT05436288
- Testing
- KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S)
- Where
- Mexico
- Volunteers
- 10 people
- Sponsor
- Kiora Pharmaceuticals, Inc.
Corneal Persistent Epithelial Defect
NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries
This study will enroll participants with a non-infected, corneal persistent epithelial defect (PED) resulting from an ocular chemical and/or thermal ocular injury which is non-responsive or refractory to current standard of care…
- Trial name
- EXPEDE (NCT04081103)
- Testing
- Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Glaukos Corporation
Postoperative Ocular Pain After PRK Surgery
Study of SAF312 as an Eye Drop for Treatment of Eye Pain Following Photorefractive Keratectomy (PRK) Surgery
The purpose of this study is to determine if SAF312 eye drops have an adequate safety and efficacy profile to justify further clinical development for the treatment of ocular pain associated with corneal epithelial defect such as…
- Trial name
- NCT02961062
- Testing
- SAF312
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals